Surging Cancer Prevenance Drives DNA Microarray Industry

The DNA microarray market was USD 1,982.1 million in 2023, and it will increase to USD 3,930.8 million, with a 10.5% compound annual growth rate, by 2030.

This is because of the rise in the occurrence of cancer across the globe, rising use of this technology in its findings, and advancements in information technology, including software.

DNA microarray has numerous applications, including disease diagnosis & monitoring, agricultural biotechnology, protein expression & proteomics, discovery of novel medication molecules, and cancer diagnosis. The increasing funding for research purposes and the rising utilization of this technology in gene expression also boosts the industry expansion.

North America led the industry in 2023, with approximately 40% share, and the regional industry will further propel at a robust rate in the years to come. This can be mainly because of the existence of major companies in this continent and the increasing funding by them to develop technologically enhanced DNA microarray products.

APAC is expected to advance at the highest rate in the years to come. This is because of the increasing funding and contributions by both foreign and local life sciences establishments and the high incidence of cancer and various other chronic illnesses in this region.

With the mounting prevalence of cancer all across the globe, the DNA microarray industry will continue to grow in the years to come.

Read More

DNA Synthesizer Market Led by Biotech Companies

The DNA synthesizer market was valued at USD 266.3 million in 2023, which will reach USD 686.1 million by 2030, rising at a rate of 14.6% by the end of this decade. This is attributed to the rising occurrence of chronic diseases, growing requirement for more-personalized therapies, expanding acceptance of gene therapy, and growing investments in R&D.

Recently, there has been a drastic increase in the prevalence of severe chronic ailments, for example immunological ailments, cancer, and genetic illnesses, all over the globe.

Nearly 50,000 congenital disorders that are an outcome of a mutation of a single gene are recognized by scientists. This is powering the acceptance of gene therapy, as it can cure severe ailments that were previously untreatable, and the outcomes are better than expected. For example, numerous people have already regained their vision with the help of gene therapy, after suffering from hereditary, gradual blindness.

Based on end user, biotech companies led the industry, with a share of 50%, in 2023. This is due to the growing biotech-related research, powered by the increasing requirement for biologic drugs, for example vaccines.

Essentially, the increasing incidence of chronic ailments has powered regional administrations to spend on life science projects so that scientists can do more-efficient treatment, substantial investments but also tech progressions, which has boosted the count of novel therapeutics becoming obtainable to patients at a global level. 

It is because of the increasing acceptance of gene therapy all over the world, the demand for DNA synthesizer is on the rise. This trend will also continue in the years to come as well.

Read More

Biological Safety Cabinet Market IS Growing Considerably in Europe

The total size of the biological safety cabinet market was USD 276.8 million in 2022, which will power at a CAGR of 7.9% by the end of this decade, to touch USD 507.1 million by 2030.

To learn more about this report: https://bit.ly/3IjgsHx

In emerging countries, governments are investing profoundly for enhancing the amenities for manufacturing biologic and pharma drugs, set up new labs, and offer better healthcare. 

The developing nations are also altering their policies for the expansion of their healthcare infra budget, for encouraging the innovation of pharma products, for example vaccines.

The class II category had the largest revenue share, about 50%, in 2022, and it will maintain its dominance in the near future as well. This is because of the high acceptance of class II biosafety cabinets since they offer strong protection to the sample, along with the user and the surrounding environment.

North America dominated the biological safety cabinet market, with about 45%, as per a report published by a market research firm P&S Intelligence, and it will grow considerably in the future, because of the substantial R&D activities in the pharma and biotech industries, accompanied by the augmented risk of communicable diseases.

Furthermore, there will be a substantial growth in  Europe, with the progression of the healthcare infra and favorable policies for taking safety initiatives for their staffs and the people. Also, there is new R&D infra for boosting the growth of region which, will power the industry.

APAC has a growing prevalence of communicable diseases; therefore, reassuring the requirement for cleanroom tech solutions, such as biological safety cabinets in healthcare surroundings. 

Furthermore, the growing acceptance of cleanroom solutions for the production and packing of biotech products is supporting the industrial growth.

Because of the rising prevalence of chronic diseases all over the world, the demand for biological safety cabinets will rise even more in the future.

Read More

How are Rising Research & Development Activities Driving Demand for Protein Assays?

As the prevalence of diseases across the globe is increasing, the demand for effective drugs and treatments is growing as well. This is leading to the increasing number investments in the pharmaceutical & biopharmaceutical research & development (R&D). As per a publication by the Pharmaceuticals Research & Manufacturers of America, about $58.8 billion were spent by the member organizations of PhRMA on R&D activities, and the amount was the highest contribution to the biopharmaceutical R&D spending in the U.S. in 2015. A number of research and development activities in the pharmaceutical and biopharmaceutical industry make use of protein assays, which is leading to their increasing demand.

These products are used in life science research for detecting the presence of protein in a sample, which is crucial for electrophoresis, atomic science, protein cleansing, cell science, and research applications. A wide variety of protein assays are available, however, it is important to consider their suitability for a specific application before usage. Each assay is characterized by some advantages and limitations, and it is not rare to obtain more than one assay for several research applications. As per a report by P&S Intelligence, the global protein assay market size is expected to advance at a significant pace in the years to come.

To learn more about this report: https://bit.ly/32ZXan1

Geographically, North America emerged as the largest protein assay market in the past, which can particularly be attributed to the increasing investments in the pharmaceutical & biopharmaceutical industry. Apart from this, the demand for protein assays is also expected to increase considerably Asia-Pacific, majorly in India, China, and Japan, in the coming years. This is because of the rising R&D spending in the life science industry and growing funding by several private and government organization for proteomic research.

In conclusion, the demand for protein assays is growing due rising expenditure in pharmaceutical and biopharmaceutical industry.

Read more: https://www.psmarketresearch.com/market-analysis/protein-assay-market

Read More

High-Throughput Screening Market is Expected to Witness the Fastest Growth in APAC During the Forecast Period

The global high-throughput screening market size is witnessing considerable growth due to increasing geriatric population, increasing healthcare expenditure, increasing research and development activities, launch of technologically advanced products that are miniaturized and automated and growing popularity of high-throughput screening for drug discovery. Moreover, high adoption of high-throughput screening models in pharmaceutical and biotechnology companies across the globe is supporting the growth of the market. Based on technology, 2D cell culture segment is expected to grow at the fastest rate during the forecast period owing to its low cost and ease of use.

The rapid growth in emerging economies and growing research and development activities on stem cells and toxicology is expected to create opportunities for the manufacturers of high-throughput screening products. However, high cost of high-throughput screening, lack of trained professionals and complexity in assay development are the key factors hampering the growth of the global market.

To Learn More About this report at: http://bit.ly/34YdFwQ

Geographically, North America has been the largest market for high-throughput screening, owing to its increased awareness, increasing government funding, established healthcare industry, and easy accessibility to advanced technologies due to the awareness in the region. The U.S. contributed largest revenue to the North American as well as global high-throughput screening market. The increased research and development activities and increasing prevalence of chronic diseases arising the need for novel treatments is the key growth driving factor for the U.S. high-throughput screening market.

Globally, the high-throughput screening market is expected to witness the fastest growth in Asia-Pacific during the forecast period. The highest growth in the region is attributed to the increasing research and development activities, increasing per capita income leading to improving standard of living, increasing healthcare spending, growing demand for better quality medical care, and awareness about high-throughput screening in the region.

The key players operating in the global market are Agilent Technologies, Inc, Danaher Corporation, Thermo Fisher Scientific Inc., Merck Millipore, Bio-Rad Laboratories, Inc., Hamilton Company and Aurora Biomed, Inc.

Read More

Agricultural Biotechnology Market and its Growth Landscape for the Next Few Years

The rising demand for biofuel and transgenic crops, growing population, regulatory support in Brazil and the U.S., and increasing per capita income are driving the agricultural biotechnology market. It generated a revenue of $28.5 billion in 2016, and it is expected to advance at a CAGR of 10.1% during the forecast period (2017–2023). The utilization of molecular biology tools and techniques, such as molecular markers, plant tissue culture, genetic engineering, and recombination, for the development of genetically superior crops and plants is termed as agricultural biotechnology.

The key factor driving the agricultural biotechnology market is the surging demand for transgenic crops. The advantages of these crops are low requirement for harmful pesticides and improved agricultural productivity. Despite the higher cost of transgenic seeds, the overall production cost of crops is lowered, as less fuel, chemical pesticides, and machinery is used. The U.S., India, Brazil, Canada, and Argentina are the major genetically modified (GM) crop-producing countries. In the coming 10 years, the commercial GM-crop profile is expected to diversify to include fruits and staples, such as rice and cassava.

To Learn More about this report at: http://bit.ly/33MMPYh

Based on product, the categories of the agricultural biotechnology market are crop protection products and transgenic seeds. During the forecast period, the crop protection product category is projected to grow faster at a 10.7% CAGR. Various advantages offered by these products, such as protecting plants and crops from weeds, harmful chemicals, and pests, would be responsible for the growth of this category.

The technology segment of the agricultural biotechnology market is subdivided into biochips, genome editing tools, synthetic biology, deoxy ribonucleic acid sequencing, and ribonucleic acid interference. Till 2023, synthetic biology is predicted to witness the fastest growth in demand at a 10.9% CAGR. The advance of this category can be ascribed to its ability to generate large gene and gene-part clusters in a single genome of a seed, which is more advantageous than traditional approaches. 

Therefore, the market for agricultural biotechnology has a bright future, aided by the rising need to fulfill the growing demand for biofuels and create nutrient-fortified crops.

Read More

How Technological Advancements Are Aiding in Cancer/Tumor Profiling Market Growth?

The changing environment and adoption of unhealthy lifestyle habits, such as tobacco consumption and smoking, exposure to harmful radiations along with other factors have led to a massive increase in the incidence of cancer.  As per the World Health Organization, global cancer burden has risen to 9.6 million cancer deaths and 18.1 million new cases in 2018.  Further, the American Cancer Society reported that in 2017, approximately 1,688,780 new cancer cases were expected to be diagnosed in the U.S. and as many as 600,920 Americans were expected to lose their lives to cancer in the same year, which translates to 1,650 patients succumbing to cancer per day. 

The International Agency of Research on Cancer has predicted that by 2030, the global cancer burden would grow to 21.7 million new cases, mainly due to the increasing aging population. Cancer is an umbrella term that represents a large group of diseases and there are more than 100 types of cancer. In this disease, multiple types of tissues are affected, which contain different biomarkers. Therefore, to correctly identify these biomarkers for diagnostic purposes, cancer/ tumor profiling is the need of the hour as certain cancer types affect specific sets of genes, which can be extremely helpful in drawing a correct diagnosis.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cancer-profiling-market

Cancer is a genetic disease, which is a result of changes that occur in the genes of cells that continue to divide uncontrollably.  As cancer affects numerous genes, the need for cancer profiling is being felt, which is done using various technologies, namely microarray, next generation sequencing (NGS), in-situ hybridization (ISH), immunohistochemistry (IHC), and quantitative polymerase chain reaction (qPCR).  During 2013–2016, the most popular technology for generating tumor/cancer profiles was the NGS. This can be credited to the immense popularity of this technology among researchers and scientists as it helps in parallelly sequencing millions of fragments per run. It is a high-throughput process which translates into sequencing of thousands of genes at a time. Further, this technology also has the scope of discovering rare or novel variants. Owing to the aforementioned factors, this technology would continue to remain a favorite among end users. This is expected to lead the cancer/tumor profiling market to witness significant growth at a 19.0% CAGR in the coming years, as estimated in a P&S Intelligence study.

To Learn More About this Report: http://bit.ly/2XEq871

Cancer/tumor profiling can be used for various purposes, such as prognostics, personalized medicine, biomarker discovery, diagnostics, and others. During 2013–2016, cancer/tumor profiling was most extensively used in the personalized medicine domain. This is attributed to the high success rates achieved in cancer treatment using personalized therapy, as it offers a tailormade treatment specific to an individual. This is expected to continue being the most popular application area of cancer profiling in the coming years as well.

Helomics Corp. and Indivumed GmBH entered into a partnership in 2017 in order to analyze annotated clinical data and human cancer biospecimens from consenting patients worldwide. Other key players in the global cancer/tumor profiling market are HTG Molecular Diagnostics Inc., NeoGenomics Inc., Caris Life Sciences Inc., Oxford Gene Technology, RiboMed Biotechnologies Inc., Illumina Inc., NanoString Technologies Inc., and Genomic Health Inc.

Read More

Cell-Based Assays Market and its Growth Landscape for the Next Few Years

Cell-based assays are commonly used analytical tools to measure the cell proliferation, viability, cytotoxicity, production and screening of compounds. Owing to the rise in cases of chronic disorders and increasing inclination of the government organizations and private firms funding in the health sector, there has been a consistent high demand of new therapeutic drug discovery. In this regard, the cell-based assays have advantage over the conventional animal based models for drug discovery. Cell-based assays utilizes live cell models to investigate the cellular mechanism when exposed to external stimuli and provide precise information about the intracellular molecular targets required in drug discovery screening.  In contrary to the animal based methods, the resultant toxicity and safety measures in cell based assays are monitored at an early stage of an experiment, hence it reduces the additional cost that can be generated due to high failure rates if monitored at a later stage of an experiment. In combination to high-throughput screening techniques, cell- based assays have gained its interest in the area of research and development for primary as well as secondary screening. However, cell-based assay’s experimental instruments and kits are expensive and require high skilled professionals to conduct the procedures as the cost of experimental procedure is relatively high. This acts as one of the key restraining factors governing the cell-based assays markets.

To Lean More About this report: http://bit.ly/33acESt

The global cell-based assays market is anticipated to grow on account of rise in the incidence of chronic diseases, increasing public and private intervention in the area of research and development, inclination towards cell-based assays over traditional biochemical assays, and a sustained increase in the drug discovery activity. According to the Centers for Disease Control and Prevention, 7 out of ten causes of death were due to chronic ailments, in 2014. Additionally, the cell-based assay techniques have many advantages over conventional methodology. The continuous advancement in technological products under cell-based assay along with their cost effectiveness are the major drivers of the growth of global cell-based assays market.

Geographically, North America has been the largest region in the global cell-based assays market, mainly attributable to the high public and private funding in the research and development field of cell-based assays market. North America is expected to remain the largest market in the global market during the period 2017 – 2023, followed by the Europe. Asia-Pacific is expected to witness the highest growth during the forecast period with, countries such as China, Japan and India expected to be the growing centers of the cell-based assay market in the region.

Some of the major players operating in the global cell-based assays market include Merck KGaA, Becton, Dickinson and Company, Promega Corporation, Danaher Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., BioTek Instruments Inc., Lonza Group, ProQinase GmbH, Charles River Laboratories Inc, Cisbio Bioassays, Miltenyi Biotec, Cell Biolabs, Inc.,  DiscoverX Corporation, BioAgilytix Labs., Enzo Life Sciences, Inc., Aurelia Bioscience Ltd., Selexis SA, and QGel SA.

Read More